PCRX Pacira BioSciences, Inc. - Common Stock
NASDAQ · Pharmaceuticals · SEC EDGAR'da Görüntüle ↗ kapat Eki 5, 2026 10-K/10-Q Ağu 4, 2026
$25,44
· 52 haftalık aralığın %'i
· düşüğün üstünde
· yükseğe
$18,8052 haftanın en düşüğü
$27,6652 haftanın en yükseği
Piyasa Değeri (MRQ)
$1.01B
P/E (TTM)
70.7
Hisse Başına Kâr (TTM)
$0.36
Gelir (TTM)
$746M
rozetleriniz
52 Haftlık Aralık
$19–$28
Analist Derecelendirmesi
BUY
Fiyat Hedefi
$30
P/E
70.7
ROE
2.0%
Net Kâr Marjı
2.0%
Rozet şeridiniz boş — bu sayfada herhangi bir metriği sabitleyin.
PCRX Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$25.44
Piyasa Değeri (MRQ)
$1.01B
P/E (TTM)
70.7
Hisse Başına Kâr (TTM)
$0.36
Gelir (TTM)
$746M
ROE (TTM)
2.0%
D/E Borç/Özsermaye (MRQ)
0.5
52 Haftlık Aralık
$19–$28
PCRX Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
aralık
çubuklar
Çubuk çözünürlüğü seçilen döneme uyum sağlar — bir çubuk için açılış/yüksek/düşük/kapanış değerlerini görmek için grafiğin üzerine gelin.
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir$726M2016-12-31 → 2025-12-31
Hisse Başına Kâr$0.162016-12-31 → 2025-12-31
Serbest Nakit Akışı$137M2016-12-31 → 2025-12-31
Net kar marjı2.0%2016-12-31 → 2025-12-31
Değerleme ve Oranlar
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
| Metrik | 5 Yıllık trend | PCRX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| P/E (TTM) | 70.75Y ort. ≈74.0 | ≈74.0 | · | · | |
| F/S (TTM) | 1.45Y ort. ≈2.5 | ≈2.5 | · | · | |
| F/D (MRQ) | 1.55Y ort. ≈2.1 | ≈2.1 | 3.7 | Düşük değerli | |
| EV / EBITDA (TTM) | 10.7 | · | · | · | |
| Fiyat / Serbest Nakit Akışı (TTM) | 5.65Y ort. ≈14.6 | ≈14.6 | · | · | |
| Fiyat / Nakit Akışı (TTM) | 5.45Y ort. ≈11.1 | ≈11.1 | · | · | |
| EV / Gelir (TTM) | 1.5 | · | · | · | |
| EV / FCF (TTM) | 6.3 | · | · | · | |
| Fiyat / Maddi Defter Değeri (MRQ) | 2.65Y ort. ≈9.5 | ≈9.5 | · | · |
Akran ortalaması, metrik başına standartlaştırılmış bir temelde hesaplanır ve bu hisse senedi için gösterilen TTM/MRQ temelini her zaman eşleşmeyebilir.
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
| Metrik | 5 Yıllık trend | PCRX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Faaliyet Kâr Marjı (TTM) | 2.7%5Y ort. ≈10.3% | ≈10.3% | -2342.9% | En üst düzey | |
| FAVÖK Marjı (TTM) | 14.1%5Y ort. ≈21.0% | ≈21.0% | -1487.9% | En üst düzey | |
| Vergi Öncesi Kar Marjı (TTM) | 2.4%5Y ort. ≈6.0% | ≈6.0% | -414.1% | En üst düzey | |
| Net Kâr Marjı (TTM) | 2.0%5Y ort. ≈4.3% | ≈4.3% | -1320.1% | En üst düzey | |
| ROA (TTM) | 1.1%5Y ort. ≈0.01% | ≈0.01% | -34.1% | En üst düzey | |
| ROE (TTM) | 2.0%5Y ort. ≈0.14% | ≈0.14% | -39.7% | En üst düzey | |
| ROIC | 0.75%5Y ort. ≈2.2% | ≈2.2% | -30.5% | En üst düzey |
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
| Metrik | 5 Yıllık trend | PCRX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Borç / Öz Sermaye (MRQ) | 0.5 | · | 0.3 | Yüksek borç | |
| Cari Oran (MRQ) | 5.05Y ort. ≈3.4 | ≈3.4 | 10.1 | Düşük likidite | |
| Cari Oran (MRQ) | 3.15Y ort. ≈2.6 | ≈2.6 | 9.0 | Düşük likidite | |
| Uzun Vadeli Borç / Özkaynak (MRQ) | 0.5 | · | 0.3 | Yüksek borç |
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
| Metrik | 5 Yıllık trend | PCRX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Revenue YoY (Gelir Yıllık Bazda) | 3.6%5Y ort. ≈11.6% | ≈11.6% | · | · | |
| Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı) | 2.9%5Y ort. ≈9.4% | ≈9.4% | · | · | |
| Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı) | 11.1% | · | · | · | |
| EPS YoY (EPS YB) | 161.8%5Y ort. ≈8.8% | ≈8.8% | · | · | |
| Net Income YoY (Net Gelir Yıllık Bazda) | 163.7%5Y ort. ≈10.2% | ≈10.2% | · | · | |
| EPS CAGR 3Y (EPS Bileşik Yıllık Büyüme Oranı 3Y) | -22.2% | · | · | · | |
| EPS CAGR 5Y (EPS Bileşik Yıllık Büyüme Oranı 5Y) | -45.5% | · | · | · | |
| Net Income CAGR 3Y (Net Gelir Bileşik Yıllık Büyüme Oranı 3Y) | -23.8% | · | · | · | |
| Net Income CAGR 5Y (Net Gelir Bileşik Yıllık Büyüme Oranı 5Y) | -45.4% | · | · | · |
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
| Metrik | 5 Yıllık trend | PCRX | 5Y ort. | Akran Ortalaması | Sonuç |
|---|---|---|---|---|---|
| Asset Turnover (Aktif Devir Hızı) | 0.55Y ort. ≈0.4 | ≈0.4 | 0.2 | En üst düzey | |
| Inventory Turnover (Stok Devir Hızı) | 1.15Y ort. ≈1.6 | ≈1.6 | · | · | |
| Receivables Turnover (Alacak Devir Hızı) | 6.15Y ort. ≈6.7 | ≈6.7 | 11.6 | Zayıf | |
| Revenue / Employee (Çalışan Başına Gelir) | ≈$880.5K | · | · | · |
değer · ≈ 5Y ort. · sektör ortalaması · ortalamaya göre değerlendirme
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
-2.3%
Sonraki Rapor
Kas 04, 2026
| Dönem | Rapor | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|---|
| 30 Haziran 2026 | Ağu 3, 2026 | $0.73 | $0.66 | 10.6% |
| 31 Mart 2026 | May 6, 2026 | $0.60 | $0.57 | 4.4% |
| 31 Aralık 2025 | $0.57 | $0.92 | -38.2% | |
| 30 Eylül 2025 | $0.70 | $0.66 | 5.3% | |
| 30 Haziran 2025 | $0.74 | $0.72 | 2.1% | |
| 31 Mart 2025 | $0.62 | $0.61 | 2.0% |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $726M | $701M | $675M | $667M | $542M | $430M | $421M | $337M | $287M | $276M | $249M | $198M | |
| Cost of Revenue | $150M | $170M | $185M | $199M | $140M | $117M | $107M | $87M | $88M | $110M | $72M | $77M | |
| R&D Expense | $117M | $82M | $76M | $85M | $56M | $59M | $72M | $56M | $57M | $46M | $29M | $19M | |
| SG&A Expense | $369M | $294M | $269M | $255M | $199M | $194M | $201M | $177M | $161M | $153M | $139M | $107M | |
| Operating Expenses | $707M | $774M | $587M | $607M | $452M | $383M | $411M | $321M | $312M | $308M | $240M | $203M | |
| Operating Income | $19M | $-73M | $88M | $60M | $90M | $46M | $10M | $16M | $-25M | $-32M | $9M | $-5M | |
| Interest Expense | · | · | $20M | $40M | $32M | $26M | $24M | $22M | $18M | $7M | $8M | $8M | |
| Interest Income | $23M | $20M | $11M | $5M | $896.0K | $5M | $7M | $6M | $4M | $1M | $678.0K | $382.0K | |
| Other Non-op | $-7M | $-373.0K | $-186.0K | $-11M | $-3M | $3M | $-5M | $-888.0K | $167.0K | $-82.0K | $-165.0K | $-159.0K | |
| Pretax Income | $17M | $-63M | $62M | $13M | $56M | $20M | $-11M | $-425.0K | $-42M | $-38M | $2M | $-14M | |
| Income Tax | $10M | $36M | $20M | $-3M | $14M | $-125M | $268.0K | $46.0K | $140.0K | $105.0K | $264.0K | $173.0K | |
| Net Income | $7M | $-100M | $42M | $16M | $42M | $146M | $-11M | $-471.0K | $-43M | $-38M | $2M | $-14M | |
| EPS (Basic) | $0.16 | $-2.15 | $0.91 | $0.35 | $0.95 | $3.41 | $-0.27 | $-0.01 | $-1.07 | $-1.02 | $0.05 | $-0.39 | |
| EPS (Diluted) | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 | $3.33 | $-0.27 | $-0.01 | $-1.07 | $-1.02 | $0.04 | $-0.39 | |
| Shares (Basic) | 44,566,000 | 46,245,000 | 46,222,000 | 45,521,000 | 44,262,000 | 42,671,000 | 41,513,000 | 40,911,000 | 39,806,000 | 37,236,000 | 36,540,000 | 35,299,000 | |
| Shares (Diluted) | 45,042,000 | 46,245,000 | 51,979,000 | 46,538,000 | 45,630,000 | 43,682,000 | 41,513,000 | 40,911,000 | 39,806,000 | 37,236,000 | 41,301,000 | 35,299,000 | |
| EBITDA | $110M | $5M | $163M | $152M | $118M | $66M | $30M | $29M | $-11M | $-19M | $21M | $5M |
Bilanço
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $159M | $277M | $153M | $104M | $586M | $100M | $78M | $133M | $54M | $36M | $54M | $38M | |
| Short-term Investments | $80M | $208M | $125M | $185M | $71M | $422M | $214M | $251M | $257M | $137M | $102M | $119M | |
| Receivables | $124M | $113M | $106M | $98M | $96M | $53M | $48M | $38M | $32M | $30M | $26M | $22M | |
| Inventory | $153M | $125M | $104M | $96M | $99M | $65M | $58M | $49M | $41M | $31M | $62M | $29M | |
| Prepaid Expense | $33M | $22M | $22M | $15M | $15M | $12M | $11M | $8M | $7M | $9M | $6M | $4M | |
| Current Assets | $548M | $745M | $510M | $498M | $866M | $652M | $409M | $478M | $391M | $243M | $253M | $214M | |
| PP&E (Net) | $141M | $167M | $174M | $184M | $188M | $137M | $105M | $109M | $107M | $101M | $90M | $61M | |
| PP&E (Gross) | $278M | $300M | $309M | $301M | $274M | $215M | $180M | $170M | $156M | $139M | $115M | $81M | |
| Accum. Depreciation | $138M | $133M | $135M | $117M | $85M | $78M | $75M | $62M | $49M | $38M | $25M | $20M | |
| Goodwill | $20M | $0 | $163M | $163M | $145M | $100M | $100M | $62M | $55M | $47M | $31M | $24M | |
| Intangibles | $368M | $426M | $483M | $541M | $624M | $97M | $104M | $0 | · | $0 | $81.0K | $403.0K | |
| Other Non-current Assets | · | · | · | · | · | · | · | $657.0K | $825.0K | $624.0K | $406.0K | $3M | |
| Total Assets | $1.26B | $1.55B | $1.57B | $1.68B | $2.08B | $1.27B | $831M | $689M | $628M | $391M | $388M | $326M | |
| Accounts Payable | $15M | $19M | $16M | $15M | $11M | $10M | $13M | $14M | $15M | $8M | $9M | $7M | |
| Accrued Liabilities | $96M | $80M | $64M | $90M | $128M | $71M | $70M | $46M | $41M | $37M | $35M | $28M | |
| Current Liabilities | $121M | $310M | $97M | $148M | $521M | $253M | $108M | $61M | $56M | $45M | $150M | $140M | |
| Capital Leases | $36M | $45M | $55M | $65M | $72M | $71M | $41M | $0 | · | · | · | · | |
| Deferred Tax | $4M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $21M | $17M | $14M | $10M | $20M | $4M | $2M | $17M | $16M | $19M | $11M | $5M | |
| Total Liabilities | $572M | $775M | $704M | $906M | $1.34B | $655M | $476M | $368M | $349M | $172M | $169M | $155M | |
| Long-term Debt | $372M | $585M | $522M | $689M | · | · | · | · | · | $109M | $104M | $103M | |
| Total Debt | $372M | · | · | · | · | · | · | · | · | $119M | $119M | $120M | |
| Common Stock | $48.0K | $47.0K | $46.0K | $46.0K | $45.0K | $44.0K | $42.0K | $41.0K | $41.0K | $37.0K | $37.0K | $36.0K | |
| Paid-in Capital | $1.06B | $1.01B | $977M | $924M | $942M | $873M | $754M | $710M | $669M | $565M | $527M | $481M | |
| Retained Earnings | $-199M | $-206M | $-107M | $-149M | $-212M | $-254M | $-399M | $-388M | $-389M | $-346M | $-308M | $-310M | |
| Treasury Stock | $177M | $25M | $0 | · | · | · | · | · | · | · | · | · | |
| AOCI | $4M | $343.0K | $247.0K | $-380.0K | $167.0K | $318.0K | $322.0K | $-280.0K | $-454.0K | $-30.0K | $-52.0K | $-80.0K | |
| Stockholders' Equity | $693M | $778M | $870M | $775M | $730M | $620M | $355M | $321M | $279M | $219M | $218M | $171M | |
| Liabilities + Equity | $1.26B | $1.55B | $1.57B | $1.68B | $2.08B | $1.27B | $831M | $689M | $628M | $391M | $388M | $326M | |
| Shares Outstanding | 41,116,739 | 47,078,000 | 46,481,000 | 45,928,000 | 44,734,000 | 43,637,000 | 41,908,148 | 41,222,799 | 40,668,877 | 37,480,952 | 36,848,319 | 36,150,620 |
Nakit Akışı
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $91M | $79M | $76M | $92M | $29M | $20M | $20M | $13M | $14M | $13M | $11M | $10M | |
| Stock-based Comp | $58M | $51M | $48M | $48M | $42M | $40M | $34M | $32M | $32M | $31M | $33M | $25M | |
| Deferred Tax | $6M | $21M | $16M | $-8M | $11M | $-127M | $-2M | $0 | $0 | · | · | · | |
| Amort. of Intangibles | $57M | $57M | $57M | $57M | $14M | $8M | $6M | $0 | $0 | $100.0K | $300.0K | $800.0K | |
| Restructuring | $4M | $9M | $1M | $0 | $0 | $-38.0K | $847.0K | $2M | · | · | · | · | |
| Other Non-cash | $-10M | $138M | $-26M | $-2M | $2M | $-2M | $30M | $4M | $15M | $27M | $-18M | $4M | |
| Operating Cash Flow | $152M | $189M | $155M | $145M | $126M | $77M | $71M | $49M | $18M | $33M | $28M | $27M | |
| CapEx | $15M | $11M | $15M | $30M | $46M | $38M | $10M | $15M | $19M | $25M | $40M | $23M | |
| Investing Cash Flow | $99M | $-83M | $78M | $-225M | $-21M | $-278M | $-128M | $21M | $-224M | · | · | · | |
| Debt Issued | · | · | · | · | · | · | · | · | · | $-4.0K | $-1M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | $-4.0K | $-1M | · | |
| Stock Repurchased | $148M | $25M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-148M | $-25M | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-370M | $17M | $-183M | $-402M | $381M | $222M | $4M | $9M | $224M | · | · | · | |
| Net Change in Cash | $-118M | $123M | $49M | $-481M | $486M | $22M | $-54M | $78M | · | · | · | · | |
| Taxes Paid | $9M | $11M | $4M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $137M | $179M | $139M | $115M | $80M | $39M | $60M | $34M | $-1M | $9M | $-12M | $4M | |
| Levered FCF | · | · | $126M | $67M | $56M | $-147M | $36M | $10M | $-20M | $2M | $-19M | $-5M |
Kârlılık
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 2.6% | · | 13.0% | 9.0% | 16.6% | 10.8% | 2.5% | 4.7% | -8.7% | -11.6% | 3.8% | -2.6% | |
| Net Margin | 0.97% | · | 6.2% | 2.4% | 7.8% | 33.9% | -2.6% | -0.14% | -14.9% | -13.7% | 0.75% | -6.9% | |
| Pretax Margin | 2.3% | · | 9.1% | 2.0% | 10.4% | 4.7% | -2.5% | -0.13% | -14.8% | -13.7% | 0.85% | -6.9% | |
| EBITDA Margin | 15.2% | · | 24.2% | 22.7% | 21.9% | 15.4% | 7.1% | 8.6% | -3.9% | -6.9% | 8.4% | 2.5% | |
| ROA | 0.50% | -6.4% | 2.6% | 0.85% | 2.5% | 13.8% | -1.5% | -0.07% | -8.4% | -9.7% | 0.52% | -5.5% | |
| ROE | 0.97% | -13.0% | 4.9% | 2.1% | 5.8% | 24.2% | -3.1% | -0.15% | -17.1% | -17.3% | 0.95% | -12.9% | |
| ROIC | 0.75% | -14.9% | 6.9% | 9.3% | 9.2% | 54.2% | 3.0% | 5.5% | -8.9% | -9.5% | 2.5% | -1.8% |
Likidite ve Solventlik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.5 | 2.4 | 5.2 | 3.4 | 1.7 | 2.6 | 3.8 | 7.9 | 7.0 | 5.4 | 1.7 | 1.5 | |
| Quick Ratio | 3.0 | 1.9 | 3.9 | 2.6 | 1.4 | 2.3 | 3.2 | 6.9 | 6.1 | 4.5 | 1.2 | 1.3 | |
| Debt / Equity | 0.5 | · | · | · | · | · | · | · | · | 0.5 | 0.5 | 0.7 | |
| LT Debt / Equity | 0.5 | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | 4.3 | 1.5 | 2.8 | 1.8 | 0.4 | 0.7 | -1.4 | -4.5 | 1.2 | -0.6 |
Verimlilik
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | · | 0.4 | 0.4 | 0.3 | 0.4 | 0.6 | 0.5 | 0.6 | 0.7 | 0.7 | 0.8 | |
| Inventory Turnover | 1.1 | 1.5 | 1.8 | 2.0 | 1.7 | 1.9 | 2.0 | 1.9 | 2.4 | 2.4 | 1.6 | 3.5 | |
| Receivables Turnover | 6.1 | · | 6.6 | 6.8 | 7.3 | 8.5 | 9.8 | 9.7 | 9.3 | 9.9 | 10.3 | 10.7 |
Hisse Başına
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $16.86 | $16.83 | $18.72 | $16.87 | $16.33 | $14.20 | $8.47 | $7.79 | $6.87 | $5.84 | $5.93 | $4.73 | |
| Revenue / Share | $16.13 | · | $12.99 | $14.33 | $11.87 | $9.84 | $10.14 | · | $7.20 | $7.42 | $6.03 | · | |
| Cash Flow / Share | $3.37 | $4.10 | $2.98 | $3.12 | $2.76 | $1.76 | $1.70 | · | $0.45 | $0.90 | $0.70 | · | |
| Cash / Share | $3.86 | $5.99 | $3.30 | $2.27 | $13.09 | $2.29 | $1.87 | $3.21 | $1.33 | $0.96 | $1.55 | $1.04 | |
| EPS (TTM) | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 | $3.33 | $-0.27 | $-0.01 | $-1.07 | $-1.02 | $0.04 | $-0.39 |
Büyüme Oranları
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 3.6% | 3.9% | 1.2% | 23.1% | 26.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 2.9% | 9.0% | 16.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.1% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | · | 161.8% | -63.0% | -72.4% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -22.2% | · | -35.6% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -45.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | · | 163.7% | -62.1% | -71.2% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -23.8% | · | -33.9% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -45.4% | · | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM)
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $726M | $701M | $675M | $667M | $542M | $430M | $421M | $337M | $287M | $276M | $249M | $198M | |
| Net Income TTM | $7M | $-100M | $42M | $16M | $42M | $146M | $-11M | $-471.0K | $-43M | $-38M | $2M | $-14M | |
| Market Cap | $1.06B | $871M | $1.57B | $1.77B | $2.69B | $2.61B | $1.90B | $1.77B | $1.86B | $1.21B | $2.83B | $3.21B | |
| Enterprise Value | $1.20B | · | · | · | · | · | · | · | · | $1.16B | $2.79B | $3.17B | |
| P/E | 161.8 | -8.8 | 37.9 | 113.6 | 65.4 | 18.0 | -167.8 | -4302.0 | -42.7 | -31.7 | 1919.8 | -227.3 | |
| P/S | 1.5 | 1.2 | 2.3 | 2.7 | 5.0 | 6.1 | 4.5 | 5.3 | 6.5 | 4.4 | 11.4 | 16.2 | |
| P/B | 1.5 | 1.1 | 1.8 | 2.3 | 3.7 | 4.2 | 5.3 | 5.5 | 6.6 | 5.5 | 13.0 | 18.7 | |
| P / Tangible Book | 3.5 | 2.5 | 7.0 | 24.9 | · | 6.2 | · | · | · | · | · | · | |
| P / Cash Flow | 7.0 | 4.6 | 10.1 | 12.2 | 21.4 | 33.9 | 26.9 | 36.3 | 104.4 | 36.2 | 97.6 | 125.8 | |
| P / FCF | 7.8 | 4.9 | 11.2 | 15.4 | 33.7 | 66.6 | 31.5 | 51.6 | -1253.6 | 138.5 | -230.5 | 895.3 | |
| EV / EBITDA | 10.9 | · | · | · | · | · | · | · | · | -60.5 | 133.3 | 650.6 | |
| EV / FCF | 8.8 | · | · | · | · | · | · | · | · | 132.3 | -227.2 | 885.0 | |
| EV / Revenue | 1.6 | · | · | · | · | · | · | · | · | 4.2 | 11.2 | 16.0 | |
| Earnings Yield | 0.62% | -11.4% | 2.6% | 0.88% | 1.5% | 5.6% | -0.60% | -0.02% | -2.3% | -3.2% | 0.05% | -0.44% |
Gelir Tablosu
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $192M | $177M | $197M | $180M | $181M | $169M | $187M | $169M | $178M | $167M | $181M | $164M | $169M | $160M | · | $167M | |
| Cost of Revenue | $44M | $36M | $40M | $34M | $41M | $34M | $40M | $39M | $44M | $47M | $48M | $40M | $48M | $49M | $62M | $51M | |
| R&D Expense | $30M | $28M | $38M | $26M | $28M | $25M | $24M | $19M | $20M | $18M | $19M | $21M | $19M | $17M | $18M | $19M | |
| SG&A Expense | $92M | $94M | $102M | $92M | $89M | $87M | $80M | $74M | $68M | $72M | $66M | $68M | $65M | $71M | $64M | $61M | |
| Operating Expenses | $188M | $170M | $195M | $173M | $173M | $167M | $163M | $308M | $150M | $154M | $148M | $146M | $130M | $163M | · | $146M | |
| Operating Income | $4M | $7M | $2M | $6M | $8M | $2M | $25M | $-140M | $28M | $13M | $33M | $18M | $40M | $-3M | $-10M | $21M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $3M | · | $3M | $4M | $10M | · | $10M | |
| Interest Income | $2M | $2M | $2M | $9M | $5M | $7M | $6M | $5M | $5M | $4M | $3M | $3M | $2M | $3M | $3M | $1M | |
| Other Non-op | $-34.0K | $-135.0K | $-172.0K | $-110.0K | $-11M | $4M | $-53.0K | $-122.0K | $-39.0K | $-159.0K | $515.0K | $-422.0K | $-269.0K | $-10.0K | $81.0K | $-11M | |
| Pretax Income | $3M | $5M | $571.0K | $10M | $-2M | $9M | $26M | $-139M | $37M | $14M | $34M | $17M | $38M | $-26M | $-18M | $2M | |
| Income Tax | $-2M | $2M | $-1M | $4M | $3M | $4M | $9M | $5M | $18M | $5M | $9M | $6M | $12M | $-7M | $-8M | $3M | |
| Net Income | $5M | $3M | $2M | $5M | $-5M | $5M | $16M | $-143M | $19M | $9M | $25M | $11M | $26M | $-20M | $-10M | $-693.0K | |
| EPS (Basic) | $0.12 | $0.07 | $0.05 | $0.12 | $-0.11 | $0.10 | $0.36 | $-3.11 | $0.41 | $0.19 | $0.55 | $0.23 | $0.56 | $-0.43 | $-0.22 | $-0.02 | |
| EPS (Diluted) | $0.12 | $0.07 | $0.05 | $0.12 | $-0.11 | $0.10 | $0.38 | $-3.11 | $0.39 | $0.19 | $0.58 | $0.23 | $0.51 | $-0.43 | $-0.19 | $-0.02 | |
| Shares (Basic) | 39,462,000 | 40,461,000 | · | 44,038,000 | 45,459,000 | 46,275,000 | · | 46,134,000 | 46,174,000 | 46,499,000 | · | 46,416,000 | 46,088,000 | 45,949,000 | · | 45,831,000 | |
| Shares (Diluted) | 40,300,000 | 40,910,000 | · | 44,459,000 | 45,459,000 | 46,526,000 | · | 46,134,000 | 50,539,000 | 52,193,000 | · | 52,067,000 | 52,054,000 | 45,949,000 | · | 45,831,000 | |
| EBITDA | $4M | $28M | · | $6M | $8M | $23M | · | $-140M | $28M | $32M | · | $18M | $40M | $17M | · | $21M |
Bilanço
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $206M | $144M | $159M | $148M | $300M | $284M | $277M | $246M | $247M | $184M | · | $99M | $87M | $36M | · | $109M | |
| Short-term Investments | $45M | $58M | $80M | $99M | $145M | $210M | $208M | $208M | $157M | $142M | · | $136M | $134M | $138M | · | $219M | |
| Receivables | $132M | $126M | $124M | $115M | $114M | $105M | $113M | $101M | $105M | $102M | · | $97M | $99M | $93M | · | $93M | |
| Inventory | $135M | $150M | $153M | $158M | $148M | $134M | $125M | $112M | $103M | $97M | · | $97M | $92M | $93M | · | $97M | |
| Prepaid Expense | $30M | $37M | $33M | $43M | $37M | $28M | $22M | $24M | $20M | $19M | · | $19M | $17M | $16M | · | $14M | |
| Current Assets | $615M | $515M | $548M | $563M | $746M | $760M | $745M | $690M | $632M | $543M | · | $447M | $429M | $376M | · | $533M | |
| PP&E (Net) | $130M | $136M | $141M | $147M | $155M | $164M | $167M | $167M | $169M | $172M | · | $176M | $180M | $182M | · | $194M | |
| PP&E (Gross) | $281M | $281M | $278M | $280M | $308M | $304M | $300M | $297M | $293M | $292M | · | $307M | $308M | $305M | · | $295M | |
| Accum. Depreciation | $151M | $145M | $138M | $133M | $153M | $140M | $133M | $130M | $124M | $120M | · | $131M | $128M | $123M | · | $102M | |
| Goodwill | $20M | $20M | $20M | $20M | $20M | $22M | $0 | $0 | $163M | $163M | $163M | $163M | $163M | $163M | · | $157M | |
| Intangibles | $285M | $353M | $368M | $382M | $423M | $435M | $426M | $440M | $455M | $469M | · | $498M | $512M | $526M | · | $581M | |
| Total Assets | $1.24B | $1.21B | $1.26B | $1.30B | $1.54B | $1.59B | $1.55B | $1.52B | $1.65B | $1.58B | · | $1.53B | $1.54B | $1.52B | · | $1.73B | |
| Accounts Payable | $18M | $14M | $15M | $18M | $30M | $23M | $19M | $19M | $19M | $9M | · | $17M | $24M | $17M | · | $13M | |
| Accrued Liabilities | $93M | $85M | $96M | $80M | $71M | $80M | $80M | $76M | $65M | $67M | · | $60M | $56M | $62M | · | $76M | |
| Current Liabilities | $122M | $109M | $121M | $107M | $313M | $315M | $310M | $306M | $93M | $93M | · | $94M | $109M | $99M | · | $132M | |
| Capital Leases | $39M | $34M | $36M | $39M | $41M | $44M | $45M | $48M | $50M | $52M | · | $57M | $60M | $62M | · | $65M | |
| Deferred Tax | $4M | $4M | $4M | $5M | $5M | $7M | $0 | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $27M | $25M | $21M | $25M | $25M | $24M | $17M | $13M | $13M | $13M | · | $12M | $12M | $12M | · | $19M | |
| Total Liabilities | $572M | $555M | $572M | $570M | $779M | $788M | $775M | $772M | $768M | $691M | · | $703M | $734M | $755M | · | $964M | |
| Long-term Debt | $363M | $368M | $372M | $377M | $580M | $583M | $585M | · | · | · | · | · | · | · | · | · | |
| Total Debt | $363M | $368M | · | $377M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $49.0K | $48.0K | $48.0K | $48.0K | $48.0K | $47.0K | $47.0K | $47.0K | $47.0K | $47.0K | · | $46.0K | $46.0K | $46.0K | · | $46.0K | |
| Paid-in Capital | $1.09B | $1.07B | $1.06B | $1.05B | $1.04B | $1.02B | $1.01B | $996M | $983M | $990M | · | $963M | $951M | $936M | · | $909M | |
| Retained Earnings | $-192M | $-196M | $-199M | $-201M | $-206M | $-202M | $-206M | $-222M | $-79M | $-98M | · | $-132M | $-143M | $-168M | · | $-139M | |
| Treasury Stock | $227M | $227M | $177M | $126M | $76M | $25M | $25M | $25M | $25M | · | · | · | · | · | · | · | |
| AOCI | $3M | $3M | $4M | $4M | $4M | $1M | $343.0K | $678.0K | $105.0K | $152.0K | · | $-10.0K | $-173.0K | $-137.0K | · | $-670.0K | |
| Stockholders' Equity | $672M | $654M | $693M | $727M | $758M | $799M | $778M | $750M | $879M | $892M | $870M | $832M | $808M | $768M | $775M | $770M | |
| Liabilities + Equity | $1.24B | $1.21B | $1.26B | $1.30B | $1.54B | $1.59B | $1.55B | $1.52B | $1.65B | $1.58B | · | $1.53B | $1.54B | $1.52B | · | $1.73B | |
| Shares Outstanding | 39,822,298 | 39,309,610 | 41,116,739 | 42,965,902 | 44,897,766 | 46,283,407 | 46,240,604 | 46,148,146 | 46,117,359 | 46,517,410 | 46,481,000 | 46,426,836 | 46,408,961 | 45,970,340 | 45,928,000 | 45,864,319 |
Nakit Akışı
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $21M | $21M | $21M | $21M | $27M | $21M | $21M | $20M | $19M | $18M | $18M | $18M | $19M | $20M | $30M | $20M | |
| Stock-based Comp | $15M | $14M | $13M | $14M | $15M | $15M | $12M | $13M | $13M | $13M | $12M | $13M | $11M | $12M | $13M | $13M | |
| Deferred Tax | · | · | $-4M | $8M | $752.0K | $1M | $4M | $1M | $13M | $3M | $7M | $5M | $11M | $-7M | $-11M | $702.0K | |
| Amort. of Intangibles | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | $14M | |
| Restructuring | · | · | $-54.0K | $4M | $0 | $0 | $808.0K | $1M | $996.0K | $6M | $0 | $173.0K | $936.0K | · | $0 | $0 | |
| Other Non-cash | · | $-12M | · | · | · | $-6M | · | · | · | $5M | · | · | · | $14M | · | · | |
| Operating Cash Flow | $57M | $26M | $44M | $61M | $12M | $35M | $33M | $54M | $53M | $49M | $48M | $44M | $43M | $19M | $42M | $43M | |
| CapEx | $1M | $3M | $218.0K | $4M | $3M | $9M | $2M | $4M | $2M | $3M | $2M | $3M | $3M | $7M | $5M | $5M | |
| Investing Cash Flow | $12M | $19M | $19M | $44M | $62M | $-26M | $-368.0K | $-52M | $-15M | $-16M | $8M | $-4M | $7M | $66M | $11M | $-48M | |
| Stock Repurchased | $0 | $50M | $48M | $50M | $50M | $0 | $0 | $0 | · | · | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | $-50M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-8M | $-59M | $-52M | $-257M | $-58M | $-3M | $-2M | $-3M | $25M | $-3M | $-2M | $-28M | $440.0K | $-154M | $-59M | $-8M | |
| Net Change in Cash | $62M | $-14M | $11M | $-153M | $17M | $7M | $31M | $-1M | $63M | $31M | $54M | $12M | $51M | $-69M | $-5M | $-13M | |
| Taxes Paid | $860.0K | $50.0K | $69.0K | $711.0K | $8M | $286.0K | $1M | $5M | $5M | $-245.0K | $2M | $1M | $594.0K | $201.0K | · | $112.0K | |
| Free Cash Flow | · | $23M | · | · | · | $27M | · | · | · | $46M | · | · | · | $13M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $44M | · | · | · | $5M | · | · |
Kârlılık
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 2.2% | 3.9% | · | 3.5% | 4.7% | 1.2% | · | -82.8% | 15.9% | 7.9% | · | 10.8% | 23.5% | -1.9% | · | 12.7% | |
| Net Margin | 2.4% | 1.6% | · | 3.0% | -2.7% | 2.9% | · | -85.1% | 10.6% | 5.4% | · | 6.6% | 15.2% | -12.2% | · | -0.41% | |
| Pretax Margin | 1.3% | 2.8% | · | 5.3% | -1.1% | 5.1% | · | -82.4% | 20.5% | 8.2% | · | 10.1% | 22.3% | -16.5% | · | 1.2% | |
| EBITDA Margin | 2.2% | 15.9% | · | 3.5% | 4.7% | 13.7% | · | -82.8% | 15.9% | 18.9% | · | 10.8% | 23.5% | 10.3% | · | 12.7% | |
| ROA | 0.33% | 0.21% | · | 0.39% | -0.30% | 0.30% | · | -9.4% | 1.2% | 0.58% | · | 0.66% | 1.6% | -1.1% | · | -0.04% | |
| ROE | 0.65% | 0.40% | · | 0.74% | -0.59% | 0.57% | · | -18.1% | 2.2% | 1.1% | · | 1.4% | 3.3% | -2.6% | · | -0.09% | |
| ROIC | 0.75% | 0.39% | · | 0.33% | 2.8% | 0.14% | · | -19.2% | 1.7% | 0.97% | · | 1.4% | 3.4% | -0.30% | · | -0.93% |
Likidite ve Solventlik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.0 | 4.7 | · | 5.3 | 2.4 | 2.4 | · | 2.3 | 6.8 | 5.8 | · | 4.8 | 3.9 | 3.8 | · | 4.1 | |
| Quick Ratio | 3.1 | 3.0 | · | 3.4 | 1.8 | 1.9 | · | 1.8 | 5.5 | 4.6 | · | 3.5 | 2.9 | 2.7 | · | 3.2 | |
| Debt / Equity | 0.5 | 0.6 | · | 0.5 | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.5 | 0.6 | · | 0.5 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 4.0 | · | 5.1 | 10.3 | -0.3 | · | 2.2 |
Verimlilik
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.4 | 0.5 | 0.5 | · | 0.4 | 0.5 | 0.5 | · | 0.6 | |
| Receivables Turnover | 1.6 | 1.5 | · | 1.7 | 1.7 | 1.6 | · | 1.7 | 1.7 | 1.7 | · | 1.7 | 1.8 | 1.7 | · | 2.3 |
Hisse Başına
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $16.87 | $16.63 | · | $16.93 | $16.88 | $17.25 | · | $16.24 | $19.07 | $19.18 | · | $17.91 | $17.41 | $16.71 | · | $16.79 | |
| Revenue / Share | $4.77 | $4.34 | · | $4.04 | $3.98 | $3.63 | · | $3.65 | $3.52 | $3.20 | · | $3.15 | $3.26 | $3.49 | · | $3.65 | |
| Cash Flow / Share | · | $0.63 | · | · | · | $0.76 | · | · | · | $0.94 | · | · | · | $0.42 | · | · | |
| Cash / Share | $5.17 | $3.67 | · | $3.44 | $6.69 | $6.13 | · | $5.33 | $5.36 | $3.96 | · | $2.13 | $1.87 | $0.77 | · | $2.39 | |
| EPS (TTM) | $0.36 | $0.13 | · | $0.49 | $-2.74 | $-2.24 | · | $-1.95 | $1.39 | $1.51 | · | $0.12 | $-0.13 | $-0.24 | · | $0.41 |
Değerleme (TTM)
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $746M | $735M | · | $717M | $706M | $703M | · | $695M | $690M | $682M | · | · | · | · | · | $654M | |
| Net Income TTM | $15M | $5M | · | $21M | $-127M | $-104M | · | $-91M | $64M | $70M | · | $7M | $-5M | $-10M | · | $21M | |
| Market Cap | $1.01B | $888M | · | $1.11B | $1.07B | $1.15B | · | $695M | $1.32B | $1.36B | · | $1.42B | $1.86B | $1.88B | · | $2.44B | |
| Enterprise Value | $1.12B | $1.05B | · | $1.24B | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 70.5 | 173.8 | · | 52.6 | -8.7 | -11.1 | · | -7.7 | 20.6 | 19.4 | · | 255.7 | -308.2 | -170.0 | · | 129.7 | |
| P/S | 1.4 | 1.2 | · | 1.5 | 1.5 | 1.6 | · | 1.0 | 1.9 | 2.0 | · | · | · | · | · | 3.7 | |
| P/B | 1.5 | 1.4 | · | 1.5 | 1.4 | 1.4 | · | 0.9 | 1.5 | 1.5 | · | 1.7 | 2.3 | 2.4 | · | 3.2 | |
| P / Tangible Book | 2.8 | 3.2 | · | 3.4 | 3.4 | 3.4 | · | 2.2 | 5.0 | 5.2 | · | 8.3 | 14.0 | 23.9 | · | 76.8 | |
| P / Cash Flow | · | 34.6 | · | · | · | 32.4 | · | · | · | 27.7 | · | · | · | 98.1 | · | · | |
| EV / Revenue | 1.5 | 1.4 | · | 1.7 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 1.4% | 0.58% | · | 1.9% | -11.5% | -9.0% | · | -13.0% | 4.9% | 5.2% | · | 0.39% | -0.32% | -0.59% | · | 0.77% |
En son dönem solda · null değerler · olarak gösterilir
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Gelir | $726M | $701M | $675M | $667M | $542M |
| Faaliyet Kâr Marjı % | 2.6% | · | 13.0% | 9.0% | 16.6% |
| Net Gelir | $7M | $-100M | $42M | $16M | $42M |
| Seyreltilmiş Hisse Başı Kâr | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Borç / Öz Sermaye | 0.5 | · | · | · | · |
| Cari Oran | 4.5 | 2.4 | 5.2 | 3.4 | 1.7 |
| Cari Oran | 3.0 | 1.9 | 3.9 | 2.6 | 1.4 |
| Metrik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $137M | $179M | $139M | $115M | $80M |
Kurumsal Sahipler (13F) 266 dosya · $1.2B toplam · Tarih itibarıyla 30 Eylül 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Sahipler
266
Tutulan Değer
$1.2B
Yeni pozisyonlar
36
Çıkan pozisyonlar
23
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 36 (0 önceki Ç'ye göre) | 23 (-16 önceki Ç'ye göre) | 79 (-8 önceki Ç'ye göre) | 85 (+5 önceki Ç'ye göre) | +308K |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| BlackRock, Inc. | $170.126.377 | 6.705.809 | 14,10% | Hisse senetleri |
| VANGUARD GROUP INC | $124.559.276 | 4.812.955 | 10,32% | Hisse senetleri |
| Doma Perpetual Capital Management LLC | $70.472.634 | 2.777.794 | 5,84% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $61.046.258 | 2.406.238 | 5,06% | Hisse senetleri |
| DIMENSIONAL FUND ADVISORS LP | $53.360.107 | 2.103.245 | 4,42% | Hisse senetleri |
| STATE STREET CORP | $52.261.616 | 2.059.977 | 4,33% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $49.479.923 | 1.950.332 | 4,10% | Hisse senetleri |
| RENAISSANCE TECHNOLOGIES LLC | $43.986.531 | 1.733.801 | 3,65% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $42.915.156 | 1.691.571 | 3,56% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $38.743.263 | 1.527.129 | 3,21% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $29.401.072 | 1.158.693 | 2,44% | Hisse senetleri |
| MORGAN STANLEY | $29.039.913 | 1.144.654 | 2,41% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $25.829.019 | 1.018.093 | 2,14% | Hisse senetleri |
| UBS Group AG | $23.345.905 | 920.217 | 1,94% | Hisse senetleri |
| Impax Asset Management Group plc | $19.028.185 | 750.027 | 1,58% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $18.383.203 | 724.604 | 1,52% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $17.525.241 | 690.786 | 1,45% | Hisse senetleri |
| GAGNON SECURITIES LLC | $15.440.613 | 608.617 | 1,28% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $14.294.929 | 563.458 | 1,18% | Hisse senetleri |
| NORTHERN TRUST CORP | $13.364.459 | 526.782 | 1,11% | Hisse senetleri |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $10.436.533 | 411.373 | 0,87% | Hisse senetleri |
| DEUTSCHE BANK AG\ | $9.922.232 | 391.101 | 0,82% | Hisse senetleri |
| Jefferies Financial Group Inc. | $9.389.234 | 370.092 | 0,78% | Hisse senetleri |
| Hillsdale Investment Management Inc. | $9.201.699 | 362.700 | 0,76% | Hisse senetleri |
| Gagnon Advisors, LLC | $8.946.401 | 352.637 | 0,74% | Hisse senetleri |
| JPMORGAN CHASE & CO | $8.698.627 | 346.697 | 0,72% | Hisse senetleri |
| EASTERLY INVESTMENT PARTNERS LLC | $8.550.172 | 337.019 | 0,71% | Hisse senetleri |
| Bridge City Capital, LLC | $7.922.975 | 312.297 | 0,66% | Hisse senetleri |
| BARCLAYS PLC | $7.869.496 | 310.189 | 0,65% | Hisse senetleri |
| Bank of New York Mellon Corp | $7.531.837 | 296.880 | 0,62% | Hisse senetleri |
| PRINCIPAL FINANCIAL GROUP INC | $7.129.402 | 281.017 | 0,59% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $6.633.164 | 261.457 | 0,55% | Hisse senetleri |
| Invesco Ltd. | $6.326.010 | 249.350 | 0,52% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $6.088.952 | 240.006 | 0,50% | Hisse senetleri |
| MILLENNIUM MANAGEMENT LLC | $5.966.085 | 235.163 | 0,49% | Hisse senetleri |
| Coppell Advisory Solutions LLC | $5.592.970 | 16 | 0,46% | Hisse senetleri |
| VICTORY CAPITAL MANAGEMENT INC | $5.562.474 | 219.254 | 0,46% | Hisse senetleri |
| FMR LLC | $5.505.316 | 217.001 | 0,46% | Hisse senetleri |
| Empowered Funds, LLC | $5.075.852 | 200.073 | 0,42% | Hisse senetleri |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $5.068.926 | 199.800 | 0,42% | Hisse senetleri |
| ROYAL BANK OF CANADA | $4.704.000 | 185.433 | 0,39% | Hisse senetleri |
| Banco Santander, S.A. | $4.211.420 | 166.000 | 0,35% | Hisse senetleri |
| Robeco Institutional Asset Management B.V. | $4.161.036 | 164.014 | 0,34% | Hisse senetleri |
| AMERIPRISE FINANCIAL INC | $4.137.744 | 163.096 | 0,34% | Hisse senetleri |
| CITADEL ADVISORS LLC | $4.114.101 | 162.164 | 0,34% | Hisse senetleri |
| AQR CAPITAL MANAGEMENT LLC | $4.021.427 | 158.511 | 0,33% | Hisse senetleri |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $3.562.811 | 140.434 | 0,30% | Hisse senetleri |
| Public Sector Pension Investment Board | $3.429.720 | 135.188 | 0,28% | Hisse senetleri |
| PDT Partners, LLC | $3.358.176 | 132.368 | 0,28% | Hisse senetleri |
| STATE OF WISCONSIN INVESTMENT BOARD | $3.292.062 | 129.762 | 0,27% | Hisse senetleri |
Aktivistler ve %5+ sahipler 16 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| DOMA PERPETUAL CAPITAL MANAGEMENT LLC, DOMA1 LLC, DOMA Perpetual LO Equity Master Fund LP, DOMA Perpetual Partners GP LLC, Pedro Escudero, The John Templeton Foundation, DOMA2 LLC, Eric de Armas ×4 başvurular | 12 Mart 2026 | 7,30% | Değişiklik | Yönetim kurulu kampanyası | SEC |
| Consonance Capital Management LP, Consonance Capman GP LLC, Mitchell Blutt ×5 başvurular | 06 Eylül 2019 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 18 Mart 2014 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 26 Temmuz 2013 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 02 Nisan 2013 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 21 Mart 2013 | · | İlk başvuru | · | SEC |
| Sanderling Venture Partners VI, L.P., Sanderling Ventures Management VI, Sanderling VI Beteiligungs GmbH & Co. KG, Sanderling VI Limited Partnership, Sanderling Venture Partners VI Co-Investment Fund, L.P., Middleton, McNeil, Mills & Associates VI, LLC, Fred A. Middleton ×4 başvurular | 21 Mart 2013 | · | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 28 Eylül 2012 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 15 Haziran 2012 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 19 Mart 2012 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 01 Aralık 2011 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 01 Aralık 2011 | · | İlk başvuru | Pasif yatırım | SEC |
| MPM BioVentures IV-QP, L.P., MPM BioVentures IV GmbH & Co. Beteiligungs KG, MPM Asset Management Investors BV4 LLC, MPM BioVentures IV GP LLC, MPM BioVentures IV LLC, Ansbert Gadicke, Luke Evnin, Steven St. Peter, Todd Foley, James Paul Scopa, Vaughn M. Kailian, John Vander Vort | 29 Kasım 2011 | · | İlk başvuru | Pasif yatırım | SEC |
| Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi, Açıklanmayan raporlama kişisi | 18 Şubat 2011 | · | İlk başvuru | · | SEC |
| Açıklanmayan raporlama kişisi | 18 Şubat 2011 | · | İlk başvuru | · | SEC |
| MPM BioVentures IV Q-P, L.P., MPM BioVentures IV GmbH & Co. Beteiligungs KG, MPM Asset Management Investors BV4 LLC, MPM BioVentures IV GP LLC, MPM BioVentures IV LLC, Ansbert Gadicke, Luke Evnin, Steven St. Peter, William Greene, James Paul Scopa, Ashley Dombkowski, Vaughn M. Kailian, John Vander Vort | 18 Şubat 2011 | · | İlk başvuru | Pasif yatırım | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Şirket yöneticileri 44 içeriden öğrenenler · 20 yöneticiler · 17 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| Frank D. Lee | Chief Executive Officer | 11 Şubat 2026 A | 660.831 | 0 | 0 | $0 |
| David M Stack | CEO and Chairman | 14 Haziran 2023 A | 186.481 | 0 | 0 | $0 |
| Shawn Cross | Chief Financial Officer | 23 Nisan 2026 M | 105.341 | 0 | 7 | $-1.521.351 |
| Max Reinhardt | President, Rest of World | 07 Haziran 2023 S | 29.225 | 0 | 0 | $0 |
| James S Scibetta | President | 05 Haziran 2017 S | 25.118 | 0 | 0 | $0 |
| Scott Braunstein | Chief Operating Officer | 03 Ocak 2018 A | 20.982 | 0 | 0 | $0 |
| Jonathan Slonin | Chief Medical Officer | 17 Ağustos 2026 S | 216.384 | 0 | 3 | $-240.431 |
| Lauren Riker | Senior Vice President, Finance | 11 Haziran 2026 S | 62.284 | 0 | 3 | $-261.266 |
| Kristen Williams | Chief Administrative Officer | 04 Haziran 2026 S | 167.062 | 0 | 2 | $-498.171 |
| Brendan Teehan | Chief Commercial Officer | 11 Şubat 2026 A | 100.934 | 0 | 0 | $0 |
| Ronald J. Ellis Jr. | Chief Strategy Officer | 07 Haziran 2023 S | 30.909 | 0 | 0 | $0 |
| Dennis Mcloughlin | Chief Customer Officer | 07 Haziran 2023 S | 38.115 | 0 | 0 | $0 |
| Anthony Molloy | Chief Lgl & Compliance Officer | 06 Haziran 2023 S | 12.877 | 0 | 0 | $0 |
| Charles Anthony Laranjeira | Chief Technical Officer | 14 Haziran 2022 M | 41.752 | 0 | 0 | $0 |
| Richard Scranton | Chief Scientific Officer | 08 Kasım 2019 M | 16.061 | 0 | 0 | $0 |
| Robert J. Weiland | Chief Commercial Officer | 04 Haziran 2018 S | 5.088 | 0 | 0 | $0 |
| James B Jones | SVP & Chief Medical Officer | 20 Kasım 2017 S | 16.823 | 0 | 0 | $0 |
| Taunia Markvicka | SVP, Chief Commercial Officer | 17 Mart 2015 M | 8.579 | 0 | 0 | $0 |
| Gary Patou | Chief Medical Officer | 07 Ağustos 2014 M | 0 | 0 | 0 | $0 |
| John Pratt | General Manager, San Diego | 13 Haziran 2013 M | 0 | 0 | 0 | $0 |
| Marcelo Bigal | Yönetim kurulu üyesi | 10 Haziran 2026 A | 17.798 | 0 | 0 | $0 |
| Alethia Young | Yönetim kurulu üyesi | 10 Haziran 2026 A | 17.798 | 0 | 0 | $0 |
| Christopher Christie | Yönetim kurulu üyesi | 10 Haziran 2026 A | 23.059 | 0 | 0 | $0 |
| Samit Hirawat | Yönetim kurulu üyesi | 10 Haziran 2026 A | 6.405 | 0 | 0 | $0 |
| Mark Froimson | Yönetim kurulu üyesi | 10 Haziran 2026 A | 26.541 | 0 | 1 | $-10.905 |
| Michael J. Yang | Yönetim kurulu üyesi | 10 Haziran 2026 A | 19.798 | 0 | 0 | $0 |
| Laura Brege | Yönetim kurulu üyesi | 10 Haziran 2026 A | 30.120 | 0 | 0 | $0 |
| Thomas G Wiggans | Yönetim kurulu üyesi | 10 Haziran 2026 A | · | 0 | 0 | $0 |
| Mark A. Kronenfeld | Yönetim kurulu üyesi | 11 Haziran 2025 A | 31.065 | 0 | 0 | $0 |
| Yvonne Greenstreet | Yönetim kurulu üyesi | 08 Haziran 2022 A | 13.247 | 0 | 0 | $0 |
| John P Longenecker PHD | Yönetim kurulu üyesi | 03 Mart 2022 M | 18.823 | 0 | 0 | $0 |
| Andreas Wicki | Yönetim kurulu üyesi | 15 Mart 2021 S | 451.324 | 0 | 0 | $0 |
| Dennis L Winger | Yönetim kurulu üyesi | 14 Haziran 2017 A | 7.490 | 0 | 0 | $0 |
| Fred A Middleton | Yönetim kurulu üyesi | 24 Haziran 2013 S | 0 | 0 | 0 | $0 |
| Luke Evnin | Yönetim kurulu üyesi | 12 Haziran 2013 A | 0 | 0 | 0 | $0 |
| HBM Healthcare Investments (Cayman) Ltd. | 10% sahip | 25 Mart 2013 S | 2.233.993 | 0 | 0 | $0 |
| Abraham Ceesay | · | 04 Eylül 2025 S | 9.039 | 0 | 0 | $0 |
| Daryl Gaugler | · | 31 Aralık 2024 A | 115.443 | 0 | 0 | $0 |
| Charles A. Reinhart III | · | 12 Haziran 2024 A | 51.867 | 0 | 0 | $0 |
| Paul J Hastings | · | 12 Haziran 2024 A | 12.724 | 0 | 0 | $0 |
| Gary W Pace | · | 08 Mart 2024 S | 22.127 | 0 | 0 | $0 |
| Roy Winston | · | 02 Ağustos 2023 S | 52.440 | 0 | 0 | $0 |
| Donald C. Manning | · | 09 Haziran 2021 A | 29.520 | 0 | 0 | $0 |
| GORDON CARL L | · | 08 Şubat 2011 C | 2.828.941 | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
ETF sahipliği 58 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| PILL · Direxion Shares ETF Trust | 1,28% | 10.029 NS | 31 Temmuz 2026 | N-PORT |
| CAFG · Pacer Funds Trust | 0,74% | 8.394 NS | 31 Temmuz 2026 | N-PORT |
| PSCH · Invesco Exchange-Traded Fund Trust … | 0,55% | 37.961 SH | 02 Ekim 2026 | Günlük |
| QQQS · Invesco Exchange-Traded Fund Trust … | 0,50% | 4.607 SH | 02 Ekim 2026 | Günlük |
| RZG · Invesco Exchange-Traded Fund Trust | 0,50% | 23.694 SH | 02 Ekim 2026 | Günlük |
| XSHQ · Invesco Exchange-Traded Fund Trust … | 0,24% | 27.368 SH | 02 Ekim 2026 | Günlük |
| SCOW · Pacer Funds Trust | 0,23% | 151 NS | 31 Temmuz 2026 | N-PORT |
| IHE · iShares Trust | 0,23% | 145.471 SH | 11 Eylül 2026 | Günlük |
| JPSE · J.P. Morgan Exchange-Traded Fund Tr… | 0,18% | 39.523 NS | 31 Temmuz 2026 | N-PORT |
| CALF · Pacer Funds Trust | 0,15% | 202.699 NS | 31 Temmuz 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,13% | 42.794 SH | 19 Ağustos 2026 | Günlük |
| FSMD · FIDELITY COVINGTON TRUST | 0,11% | 104.986 NS | 31 Temmuz 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,11% | 30.919 SH | 19 Ağustos 2026 | Günlük |
| VIOG · VANGUARD ADMIRAL FUNDS | 0,11% | 46.835 SH | 19 Ağustos 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0,08% | 86.154 SH | 02 Ekim 2026 | Günlük |
| DFSV · Dimensional ETF Trust | 0,07% | 231.891 NS | 31 Temmuz 2026 | N-PORT |
| SMDX · Tidal Trust III | 0,07% | 3.450 NS | 31 Temmuz 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0,07% | 2.809 SH | 02 Ekim 2026 | Günlük |
| QVMS · Invesco Exchange-Traded Fund Trust … | 0,06% | 5.956 SH | 02 Ekim 2026 | Günlük |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,06% | 31.734 SH | 19 Ağustos 2026 | Günlük |
| ROSC · Lattice Strategies Trust | 0,05% | 1.241 NS | 31 Temmuz 2026 | N-PORT |
| VIOO · VANGUARD ADMIRAL FUNDS | 0,05% | 137.158 SH | 19 Ağustos 2026 | Günlük |
| RWJ · Invesco Exchange-Traded Fund Trust … | 0,05% | 36.708 SH | 02 Ekim 2026 | Günlük |
| VFQY · VANGUARD WELLINGTON FUND | 0,04% | 7.883 SH | 19 Ağustos 2026 | Günlük |
| DFAT · Dimensional ETF Trust | 0,04% | 204.980 NS | 31 Temmuz 2026 | N-PORT |
| RSSL · Global X Funds | 0,03% | 18.945 NS | 31 Temmuz 2026 | N-PORT |
| IWM · iShares Trust | 0,03% | 1.024.328 SH | 11 Eylül 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,03% | 228.207 SH | 19 Ağustos 2026 | Günlük |
| PKW · Invesco Exchange-Traded Fund Trust | 0,03% | 19.806 SH | 02 Ekim 2026 | Günlük |
| EBIT · Harbor ETF Trust | 0,02% | 106 NS | 31 Temmuz 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,02% | 542.974 SH | 19 Ağustos 2026 | Günlük |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,02% | 2.098 SH | 02 Ekim 2026 | Günlük |
| DFAS · Dimensional ETF Trust | 0,02% | 90.095 NS | 31 Temmuz 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 17.794 NS | 31 Temmuz 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,01% | 453.622 SH | 19 Ağustos 2026 | Günlük |
| VB · VANGUARD INDEX FUNDS | 0,01% | 854.717 SH | 19 Ağustos 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | 0,01% | 112.735 SH | 19 Ağustos 2026 | Günlük |
| TILT · FlexShares Trust | 0,01% | 7.900 NS | 31 Temmuz 2026 | N-PORT |
| WSML · iShares Trust | 0,01% | 2.019 SH | 11 Eylül 2026 | Günlük |
| DFAC · Dimensional ETF Trust | 0,01% | 118.628 NS | 31 Temmuz 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,01% | 1.277 NS | 31 Temmuz 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0,01% | 6.433 NS | 31 Temmuz 2026 | N-PORT |
| IWO · iShares Trust | 0,01% | 28.461 SH | 11 Eylül 2026 | Günlük |
| DFAU · Dimensional ETF Trust | 0,00% | 9.932 NS | 31 Temmuz 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 69.932 SH | 11 Eylül 2026 | Günlük |
| DFUS · Dimensional ETF Trust | 0,00% | 12.671 NS | 31 Temmuz 2026 | N-PORT |
| IWV · iShares Trust | 0,00% | 12.150 SH | 11 Eylül 2026 | Günlük |
| DFUV · Dimensional ETF Trust | 0,00% | 866 NS | 31 Temmuz 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 1.198.792 SH | 19 Ağustos 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3.506 SH | 19 Ağustos 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 3.388 SH | 19 Ağustos 2026 | Günlük |
| IJR · iShares Trust | · | 2.397.496 SH | 10 Eylül 2026 | Günlük |
| IJT · iShares Trust | · | 374.609 SH | 09 Eylül 2026 | Günlük |
| IWN · iShares Trust | · | 338.098 SH | 11 Eylül 2026 | Günlük |
| XJR · iShares Trust | · | 5.453 SH | 31 Ağustos 2026 | Günlük |
| ISCB · iShares Trust | · | 1.678 SH | 11 Eylül 2026 | Günlük |
| ISCV · iShares Trust | · | 8.216 SH | 11 Eylül 2026 | Günlük |
| SMMV · iShares Trust | · | 12.184 SH | 19 Ağustos 2026 | Günlük |
PCRX Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
derecelendirme · 13 analist
AL
Medyan hedef
$30.00
+17,9%
3 23,1%
Güçlü Al
6 46,2%
Al
3 23,1%
Tut
1 7,7%
Sat
0 0,0%
Güçlü Sat
12 Aylık Fiyat Hedefi
9 analist · 2026-10-01Ortalama hedef $30.00 +17,9%
Şimdi
Mevcut fiyat $25.44
Düşük$23.00
Ortalama$30.00
Yüksek$38.00
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
Mali yıl bazında, fiyatlar her şirketin son mali yıl kapanışına göredir.
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | · |
| HROW | $1.82B | -350.0 | 36.4% | -1.9% | -8.4% | 75.0% |
| YARW | · | · | · | · | · | · |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| SPTX | · | · | · | · | · | · |
| ANRO | $568M | -8.1 | · | · | -46.1% | · |
| ALMS | · | -3.4 | · | -1011.8% | -61.9% | · |
| APMD | · | · | · | · | · | · |
| SGP | · | · | · | · | 50.0% | · |
| LLY | · | 46.8 | 44.7% | 31.7% | 101.2% | · |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
Sizin için önemli olan metrikleri seçin — Yukarıdaki Tam Temeller bölümündeki herhangi bir satırın yanındaki + işaretine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kaynak: SEC 10-Q dosyalandı Ağu 4, 2026